<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>metastatic uveal melanoma &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/metastatic-uveal-melanoma/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 11 Oct 2026 13:42:30 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>metastatic uveal melanoma &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Conformation-Selective PI3Kδ Inhibitor Roginolisib Shows Safety and Survival Signals in First-in-Human Cancer Trial</title>
		<link>https://bioengineer.org/conformation-selective-pi3k%ce%b4-inhibitor-roginolisib-shows-safety-and-survival-signals-in-first-in-human-cancer-trial/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sun, 11 Oct 2026 13:42:30 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[first-in-human trial]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[mass cytometry]]></category>
		<category><![CDATA[metastatic uveal melanoma]]></category>
		<category><![CDATA[Nature Communications]]></category>
		<category><![CDATA[overall survival]]></category>
		<category><![CDATA[Pharmacokinetics]]></category>
		<category><![CDATA[PI3Kδ inhibitor]]></category>
		<category><![CDATA[regulatory T cells]]></category>
		<category><![CDATA[roginolisib]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=414564</guid>

					<description><![CDATA[A first-in-human trial shows that the conformation-selective PI3Kδ inhibitor roginolisib is well tolerated in advanced cancers and is associated with median overall survival of up to 20.8 months in metastatic uveal melanoma, alongside immune changes consistent with relief of tumour-induced immunosuppression.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">414564</post-id>	</item>
	</channel>
</rss>
